Amyloid-beta clearance in Alzheimer's disease / topic editors: Robert A. Marr and Eliezer Masliah.
Strong evidence continues to accumulate indicating that amyloid-beta (Aβ) is a central part of Alzheimer’s disease (AD) pathogenesis in spite of the negative evidence coming from failed clinical trials. Therefore, mechanisms of clearance of Aβ are of great interest in understanding AD pathogenesis a...
Saved in:
| Superior document: | Frontiers in aging neuroscience |
|---|---|
| : | |
| Place / Publishing House: | [Place of publication not identified] : : Frontiers Media SA,, 2015. ©2015 |
| Year of Publication: | 2015 |
| Language: | English |
| Series: | Frontiers in aging neuroscience.
|
| Physical Description: | 1 online resource (111 pages) :; illustrations; digital, PDF file(s). |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| id |
993547173004498 |
|---|---|
| ctrlnum |
(CKB)3710000000586918 (oapen)https://directory.doabooks.org/handle/20.500.12854/40785 (EXLCZ)993710000000586918 |
| collection |
bib_alma |
| record_format |
marc |
| spelling |
Robert Marr auth Amyloid-beta clearance in Alzheimer's disease [electronic resource] / topic editors: Robert A. Marr and Eliezer Masliah. Frontiers Media SA 2015 [Place of publication not identified] : Frontiers Media SA, 2015. ©2015 1 online resource (111 pages) : illustrations; digital, PDF file(s). text txt rdacontent computer c rdamedia online resource cr rdacarrier text file PDF rda Frontiers research topics Frontiers in aging neuroscience Includes bibliographical references. Open access Unrestricted online access star Strong evidence continues to accumulate indicating that amyloid-beta (Aβ) is a central part of Alzheimer’s disease (AD) pathogenesis in spite of the negative evidence coming from failed clinical trials. Therefore, mechanisms of clearance of Aβ are of great interest in understanding AD pathogenesis and the development of effective treatments. This topic focuses on the issues related to Aβ clearance in AD. The topics covered include proteases that degrade Aβ and their localization, regulation, and functions. This topic also covers issues related to clearance through uptake by glia and through low-density lipoprotein (LDL) receptor mediated mechanisms. Signal transduction related to AD pathology and clearance is also addressed. Finally, immunotherapy and other novel therapeutic approaches are discussed. Description based on e-publication, viewed on July 24, 2018. English Alzheimer's disease. Alzheimer's disease Pathogenesis. Alzheimer's disease Molecular aspects. Neurosciences. amyloid-beta Signal Transduction Proteases LDL receptors Clearance Alzheimer's disease 2-88919-443-4 Eliezer Masliah auth Frontiers in aging neuroscience. |
| language |
English |
| format |
Electronic eBook |
| author |
Robert Marr |
| spellingShingle |
Robert Marr Amyloid-beta clearance in Alzheimer's disease Frontiers research topics Frontiers in aging neuroscience |
| author_facet |
Robert Marr Eliezer Masliah |
| author_variant |
r m rm |
| author2 |
Eliezer Masliah |
| author2_variant |
e m em |
| author_sort |
Robert Marr |
| title |
Amyloid-beta clearance in Alzheimer's disease |
| title_full |
Amyloid-beta clearance in Alzheimer's disease [electronic resource] / topic editors: Robert A. Marr and Eliezer Masliah. |
| title_fullStr |
Amyloid-beta clearance in Alzheimer's disease [electronic resource] / topic editors: Robert A. Marr and Eliezer Masliah. |
| title_full_unstemmed |
Amyloid-beta clearance in Alzheimer's disease [electronic resource] / topic editors: Robert A. Marr and Eliezer Masliah. |
| title_auth |
Amyloid-beta clearance in Alzheimer's disease |
| title_new |
Amyloid-beta clearance in Alzheimer's disease |
| title_sort |
amyloid-beta clearance in alzheimer's disease |
| series |
Frontiers research topics Frontiers in aging neuroscience |
| series2 |
Frontiers research topics Frontiers in aging neuroscience |
| publisher |
Frontiers Media SA Frontiers Media SA, |
| publishDate |
2015 |
| physical |
1 online resource (111 pages) : illustrations; digital, PDF file(s). |
| isbn |
2-88919-443-4 |
| illustrated |
Illustrated |
| dewey-hundreds |
600 - Technology |
| dewey-tens |
610 - Medicine & health |
| dewey-ones |
616 - Diseases |
| dewey-full |
616.831 |
| dewey-sort |
3616.831 |
| dewey-raw |
616.831 |
| dewey-search |
616.831 |
| work_keys_str_mv |
AT robertmarr amyloidbetaclearanceinalzheimersdisease AT eliezermasliah amyloidbetaclearanceinalzheimersdisease |
| status_str |
n |
| ids_txt_mv |
(CKB)3710000000586918 (oapen)https://directory.doabooks.org/handle/20.500.12854/40785 (EXLCZ)993710000000586918 |
| carrierType_str_mv |
cr |
| hierarchy_parent_title |
Frontiers in aging neuroscience |
| is_hierarchy_title |
Amyloid-beta clearance in Alzheimer's disease |
| container_title |
Frontiers in aging neuroscience |
| author2_original_writing_str_mv |
noLinkedField |
| _version_ |
1796652221286318080 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02625nam a2200517 i 4500</leader><controlfield tag="001">993547173004498</controlfield><controlfield tag="005">20231130164743.0</controlfield><controlfield tag="006">m fo d 000 00</controlfield><controlfield tag="007">cr#c|#---|||||</controlfield><controlfield tag="008">160208s2015uuuuxx ad||fob 000-0 eng|d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000586918</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/40785</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000586918</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="d">UkMaJRU</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="0"><subfield code="a">616.831</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Robert Marr</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Amyloid-beta clearance in Alzheimer's disease</subfield><subfield code="h">[electronic resource] /</subfield><subfield code="c">topic editors: Robert A. Marr and Eliezer Masliah.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2015</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Place of publication not identified] :</subfield><subfield code="b">Frontiers Media SA,</subfield><subfield code="c">2015.</subfield></datafield><datafield tag="264" ind1=" " ind2="4"><subfield code="c">©2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (111 pages) :</subfield><subfield code="b">illustrations; digital, PDF file(s).</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">text file</subfield><subfield code="b">PDF</subfield><subfield code="2">rda</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Frontiers research topics</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Frontiers in aging neuroscience</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="a">Open access</subfield><subfield code="f">Unrestricted online access</subfield><subfield code="2">star</subfield></datafield><datafield tag="520" ind1="3" ind2=" "><subfield code="a">Strong evidence continues to accumulate indicating that amyloid-beta (Aβ) is a central part of Alzheimer’s disease (AD) pathogenesis in spite of the negative evidence coming from failed clinical trials. Therefore, mechanisms of clearance of Aβ are of great interest in understanding AD pathogenesis and the development of effective treatments. This topic focuses on the issues related to Aβ clearance in AD. The topics covered include proteases that degrade Aβ and their localization, regulation, and functions. This topic also covers issues related to clearance through uptake by glia and through low-density lipoprotein (LDL) receptor mediated mechanisms. Signal transduction related to AD pathology and clearance is also addressed. Finally, immunotherapy and other novel therapeutic approaches are discussed.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on e-publication, viewed on July 24, 2018.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Alzheimer's disease.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Alzheimer's disease</subfield><subfield code="x">Pathogenesis.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Alzheimer's disease</subfield><subfield code="x">Molecular aspects.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Neurosciences.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">amyloid-beta</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Signal Transduction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Proteases</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">LDL receptors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Clearance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Alzheimer's disease</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-443-4</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Eliezer Masliah</subfield><subfield code="4">auth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Frontiers in aging neuroscience.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-01 00:39:20 Europe/Vienna</subfield><subfield code="d">00</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2016-02-13 18:39:49 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338434460004498&Force_direct=true</subfield><subfield code="Z">5338434460004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338434460004498</subfield></datafield></record></collection> |